Medtronic plc (MDT)
MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G
Medtronic secures FDA milestones for its MiniMed 780G system, expanding use to type 2 diabetes and enabling sensor integration.
Medtronic Plc (MDT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Medtronic plc (NYSE:MDT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive VP & CFO Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Okay. Good morning.
Here's Why Medtronic (MDT) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Medtronic makes two key additions to its board. How activist Elliott can build shareholder value
The stage seems to be set for a long-term mutually beneficial relationship between the parties.
Medtronic: Earnings Are Solid, New Board Additions Add Intrigue
Medtronic delivered solid earnings, with standout growth in Cardiovascular, but overall performance remains mixed due to weaker Neuroscience and MedSurg segments. Elliott Management's activist involvement and new board appointments could drive operational improvements and strategic divestitures, echoing past success at Cardinal Health. Valuation is attractive on a PEG basis, but I remain on hold, awaiting clear evidence of sustainable earnings momentum and operational execution.
Why Medtronic (MDT) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic: The Opportunity Gets Healthier for Income Investors
Medtronic's NYSE: MDT FQ1 results and guidance update did not spark a rally in the share price. Still, they did affirm a robust outlook that includes accelerating business growth, improving profitability, and reversing the stock price action.
Medtronic plc (MDT) Q1 2026 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q1 2026 Earnings Conference Call August 19, 2025 8:00 AM ET Company Participants Geoffrey Straub Martha - Chairman of the Board & CEO Michael Marinaro - Executive VP & President of Medical Surgical Portfolio and Americas Que Thanh Dallara - Executive VP & President Diabetes Operating Unit Ryan Weispfenning - VP & Head of Investor Relations Thierry Pieton - Executive VP & CFO Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Joanne Karen Wuensch - Citigroup Inc. Exchange Research Joshua Thomas Jennings - TD Cowen, Research Division Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division Matthew Oliver O'Brien - Piper Sandler & Co., Research Division Matthew Stephan Miksic - Barclays Bank PLC, Research Division Michael Holden Kratky - Leerink Partners LLC, Research Division Robert Justin Marcus - JPMorgan Chase & Co, Research Division Travis Lee Steed - BofA Securities, Research Division Ryan Weispfenning Hello, everyone, and thanks for joining us today for our fiscal '26 first quarter video earnings webcast.
MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up
Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.
Medtronic (MDT) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q1 Earnings and Revenues Top Estimates
Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.23 per share a year ago.
